8/26/2013

Use of cytokeratin-18 levels alone proved inadequate in evaluating the severity of fibrosis as well as differentiating nonalcoholic fatty liver disease from nonalcoholic steatohepatitis, according to a study in the Journal of Hepatology that included 229 patients who were diagnosed using magnetic resonance imaging and spectroscopy. "However, combining this variable with other biologically plausible markers may ultimately prove to be more accurate at diagnosing NASH and determining fibrosis severity," researchers said.

Related Summaries